Conversely, in early-stage or obesity-driven T2D characterized by hyperphagia and rapid gastric emptying, PYY may complement existing incretin therapy through appetite control and improved insulin sensitivity at peripheral sites [26]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.